Home LiteratureArticle Details
PMID: 9192676 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Virus dynamics and drug therapy.

Proceedings of the National Academy of Sciences of the United States of America ·Vol. 94 ·No. 13 ·1997-06-24 ·Pages 6971-6

Bonhoeffer S, May RM, Shaw GM, Nowak MA

Abstract

The recent development of potent antiviral drugs not only has raised hopes for effective treatment of infections with HIV or the hepatitis B virus, but also has led to important quantitative insights into viral dynamics in vivo. Interpretation of the experimental data depends upon mathematical models that describe the nonlinear interaction between virus and host cell populations. Here we discuss the emerging understanding of virus population dynamics, the role of the immune system in limiting virus abundance, the dynamics of viral drug resistance, and the question of whether virus infection can be eliminated from individual patients by drug treatment.

MeSH Terms
Animals Humans Models, Biological Models, Theoretical Virus Physiological Phenomena Virus Replication
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Bonhoeffer S
Department of Zoology, University of Oxford, South Parks Road, OX1 3PS, Oxford, United Kingdom.
May R M
Shaw G M
Nowak M A
References (56)
56 references, click to expand
  1. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.
    Hepatology. 1996 Sep;24(3):711-3 PMID: 8781347
  2. Anti-CD4 therapy for AIDS suggested by mathematical models.
    Proc Biol Sci. 1996 Jul 22;263(1372):899-905 PMID: 8760492
  3. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo.
    J Immunol. 1996 Nov 1;157(9):4212-21 PMID: 8892659
  4. Quantitative image analysis of HIV-1 infection in lymphoid tissue.
    Science. 1996 Nov 8;274(5289):985-9 PMID: 8875941
  5. HIV-1 evolution and disease progression.
    Science. 1996 Nov 8;274(5289):1008-11 PMID: 8966557
  6. HIV viral dynamics.
    AIDS. 1996 Dec;10 Suppl 3:S75-84 PMID: 8970715
  7. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model.
    J Virol. 1997 Jan;71(1):161-8 PMID: 8985335
  8. Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection.
    Proc Natl Acad Sci U S A. 1996 Dec 24;93(26):15323-8 PMID: 8986810
  9. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.
    Nat Med. 1997 Feb;3(2):205-11 PMID: 9018240
  10. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.
    Nat Med. 1997 Feb;3(2):212-7 PMID: 9018241
  11. Focusing on the second phase of plasma HIV-1 RNA clearance.
    AIDS. 1997 Feb;11(2):264-6 PMID: 9030385
  12. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection.
    Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1890-5 PMID: 9050875
  13. HIV-1: gambling on the evolution of drug resistance?
    Nat Med. 1997 Mar;3(3):268-71 PMID: 9055846
  14. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations.
    J Theor Biol. 1997 Jan 21;184(2):203-17 PMID: 9059598
  15. Human immunodeficiency virus drug therapy and virus load.
    J Virol. 1997 Apr;71(4):3275-8 PMID: 9060694
  16. Dynamic multidrug therapies for HIV: a control theoretic approach.
    J Theor Biol. 1997 Mar 7;185(1):15-29 PMID: 9093552
  17. Decay characteristics of HIV-1-infected compartments during combination therapy.
    Nature. 1997 May 8;387(6629):188-91 PMID: 9144290
  18. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
    Science. 1989 Mar 31;243(4899):1731-4 PMID: 2467383
  19. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Science. 1989 Dec 1;246(4934):1155-8 PMID: 2479983
  20. Zidovudine resistance of human immunodeficiency virus.
    Rev Infect Dis. 1990 Jul-Aug;12 Suppl 5:S507-10; discussion S510-2 PMID: 2201072
  21. Population dynamics of HIV within an individual after treatment with zidovudine.
    AIDS. 1991 May;5(5):485-9 PMID: 1677807
  22. Antigenic diversity thresholds and the development of AIDS.
    Science. 1991 Nov 15;254(5034):963-9 PMID: 1683006
  23. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.
    Nature. 1991 Dec 12;354(6353):453-9 PMID: 1721107
  24. Competition between zidovudine-sensitive and zidovudine-resistant strains of HIV.
    AIDS. 1992 Jan;6(1):71-9 PMID: 1543568
  25. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment.
    AIDS. 1992 Nov;6(11):1259-64 PMID: 1282015
  26. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.
    Nature. 1993 Mar 25;362(6418):355-8 PMID: 8455722
  27. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.
    Nature. 1993 Mar 25;362(6418):359-62 PMID: 8096068
  28. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
    J Virol. 1994 Mar;68(3):1660-6 PMID: 7509000
  29. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection.
    AIDS. 1994 Mar;8(3):323-32 PMID: 7913327
  30. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes.
    Cell. 1994 Aug 12;78(3):373-87 PMID: 7914835
  31. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor.
    J Virol. 1995 Feb;69(2):701-6 PMID: 7815532
  32. AIDS. Virological mayhem.
    Nature. 1995 Jan 12;373(6510):102 PMID: 7816085
  33. Viral dynamics in human immunodeficiency virus type 1 infection.
    Nature. 1995 Jan 12;373(6510):117-22 PMID: 7529365
  34. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.
    Nature. 1995 Jan 12;373(6510):123-6 PMID: 7816094
  35. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy.
    Science. 1995 Jan 27;267(5197):483-9 PMID: 7824947
  36. Drug resistance in viruses.
    Trends Microbiol. 1994 Oct;2(10):401-7 PMID: 7850209
  37. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy.
    Lancet. 1995 Apr 1;345(8953):820-4 PMID: 7534858
  38. HIV results in the frame. Results confirmed.
    Nature. 1995 May 18;375(6528):193 PMID: 7746311
  39. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
    J Infect Dis. 1995 Jun;171(6):1411-9 PMID: 7539472
  40. Antigenic oscillations and shifting immunodominance in HIV-1 infections.
    Nature. 1995 Jun 15;375(6532):606-11 PMID: 7791879
  41. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.
    J Virol. 1995 Aug;69(8):5087-94 PMID: 7541846
  42. Hepatitis B virus immunopathogenesis.
    Annu Rev Immunol. 1995;13:29-60 PMID: 7612225
  43. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Science. 1995 Aug 4;269(5224):696-9 PMID: 7542804
  44. A preliminary trial of lamivudine for chronic hepatitis B infection.
    N Engl J Med. 1995 Dec 21;333(25):1657-61 PMID: 7477217
  45. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
    N Engl J Med. 1995 Dec 21;333(25):1662-9 PMID: 7477218
  46. Immunology taught by viruses.
    Science. 1996 Jan 12;271(5246):173-8 PMID: 8539616
  47. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.
    Immunity. 1996 Jan;4(1):25-36 PMID: 8574849
  48. Population dynamics of immune responses to persistent viruses.
    Science. 1996 Apr 5;272(5258):74-9 PMID: 8600540
  49. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.
    Science. 1996 Mar 15;271(5255):1582-6 PMID: 8599114
  50. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection.
    Science. 1996 Apr 26;272(5261):537-42 PMID: 8614801
  51. Viral dynamics in hepatitis B virus infection.
    Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4398-402 PMID: 8633078
  52. Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.
    Proc Natl Acad Sci U S A. 1996 May 28;93(11):5501-6 PMID: 8643604
  53. T-cell homeostasis, competition, and drift: AIDS as HIV-accelerated senescence of the immune repertoire.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul;12(3):233-48 PMID: 8673527
  54. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay.
    Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7247-51 PMID: 8692977
  55. Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T lymphocytes.
    J Virol. 1996 Sep;70(9):5799-806 PMID: 8709196
  56. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.
    Hepatology. 1996 Sep;24(3):714-7 PMID: 8781348
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
DOI
10.1073/pnas.94.13.6971
Published
1997-06-24
Pages
6971-6
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC21269
Subset
IM
Grants
Wellcome Trust · United Kingdom
External Links
PubMed source DOI: 10.1073/pnas.94.13.6971 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2